Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

Archive ouverte

Chevallier, Patrice | Szydlo, Richard M | Blaise, Didier | Tabrizi, Reza | Michallet, Mauricette | Uzunov, Madalina | Fegueux, Nathalie | Guilhot, François | Lapusan, Simona | Gratecos, Nicole | Cahn, Jean-Yves | Socié, Gerard | Yakoub-Agha, Ibrahim | Huynh, Anne | Francois, Sylvie | Bay, Jacques-Olivier | Maury, Sébastien | Buzyn, Agnes | Contentin, Nathalie | Mohty, Mohamad

Edité par CCSD ; Elsevier -

International audience. This retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the specific aim to compare outcomes of patients between 60 and 65 years old (N = 493) with those older than 65 years (N = 107). Except for donor age, there were no significant differences between the groups regarding patients, diseases, and allo-HSCT characteristics. At time of RIC allo-HSCT, 276 patients (46%) were in complete remission. With a median follow-up of 22.8 and 23.7 months in the younger and the older groups, respectively, 2-year relapse, nonrelapse mortality, disease-free survival, and overall survival rates were similar in both groups (29.6% vs. 20.4%; 29.9% vs. 34.6%; 40.6% vs. 46.7%; 49.2% vs. 50.2%, respectively; P = NS for all comparisons). In a Cox multivariate analysis, after adjustment for disease and transplant factors, age per se was not an adverse factor for survival (relative risk = 1.08; 95% confidence interval, 0.81-1.44, P = .62). We conclude that in selected patients, RIC allo-HSCT could be offered to patients over 65 years old.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion